Conversion from mycophenolate mofetil (MMF, CellCept) to enteric-coated mycophenolate sodium (EC-MPS, myfortic) is safe and effective in renal transplant ...

Our conclusion is that a 250 mg/180 mg CellCept/Myfortic conversion ratio seems to be well tolerated; however, additional MPA measurements are warranted to ...

The 3 months interim analysis suggests that renal transplant patients receiving MMF can be converted to EC-MPS with no efficacy or tolerability compromise.

Our results suggested that converting patients with gastrointestinal complaints from MMF to equimolar doses of EC-MMF reduced gastrointestinal-related symptom ...

Conversion to equimolar doses is necessary. Mycophenolate mofetil 500 mg is considered equivalent to mycophenolate sodium 360 mg (Ref). IV and oral doses of ...

22 окт. 2024 г. · In some patients, it is necessary to convert from MMF (CellCept) to EC-MPS (Myfortic) to improve GI tolerability.

25 авг. 2021 г. · The brand name is CELLCEPT. The equivalent doses of MYFORTIC are 180mg and 360mg respectively. Monitoring: Monitoring of MMF blood levels is not ...

The 3-month interim analyses suggest that the conversion from MMF to EC-MPS is well tolerated in maintenance renal transplant recipients.

13 нояб. 2018 г. · This study demonstrates that there is no good evidence supporting the conversion from mycophenolate mofetil to enteric-coated mycophenolate ...

Does conversion from Mycophenolate Mofetil (CellCept) to Enteric-coated Mycophenolate Sodium (Myfortic) improve gastrointestinal symptoms in pediatric ...